ltiple sclerosis (GPR17), osteoarthritis (GPR22), motor control (GPR139), congenital cataracts and birth defects of the brain and spinal cord (GPR161), regulation of hematopoietic stem cell differentiation (GPR171), cancer stem cells and the self-renewal and maintenance of adult stem cells (LGR4), long-term wound repair, including the formation of new hair follicles (LGR6) and pain (MRGE). In addition, Omeros has unlocked GPR20, GPR45, GPR135, GPR162, MRGF and OPN5, which have not yet been definitively tied to any specific indications but are expressed preferentially in the gastrointestinal tract (GPR20), brain (GPR45, GPR135 and GPR162) and eye, brain, testes, spinal cord (OPN5) and dorsal root ganglia (MRGF).
About G Protein-Coupled Receptors
GPCRs, which mediate key physiological processes in the body, are one of the most valuable families of drug targets. According to Insight Pharma Reports, GPCR-targeting drugs represent 30 to 40 percent of marketed pharmaceuticals. Examples include Claritin® (allergy), Zantac® (ulcers and reflux), OxyContin® (pain), Lopressor® (high blood pressure), Imitrex® (migraine headache), Reglan® (nausea) and Abilify® (schizophrenia, bipolar disease and depression) as well as all other antihistamines, opioids, alpha and beta blockers, serotonergics and dopaminergics.
The industry focuses its GPCR drug discovery efforts mostly on non-sensory GPCRs. Of the 363 total non-sensory GPCRs, approximately 240 have known ligands (molecules that bind the receptors) with nearly half of those targeted either by marketed drugs (46 GPCRs) or by drugs in development (about 80 GPCRs). There are approximately 120 GPCRs with no known ligands, which are termed "orphan GPCRs." Without a known ligand, drug development for a given receptor is extremely difficult.
Omeros uses its proprietary high-throughput CRA to identify small-molecule agonists, antagonists and allosteric modulators for orPage: 1 2 3 4 5 Related medicine technology :1
. Omeros Announces Positive OMS721 Data in Model of Thrombotic Microangiopathy2
. Omeros to Present at the 2013 Future Leaders in the Biotech Industry Conference3
. Omeros Announces Toxicology Data that Support Advancing MASP-2 Inhibitor into Clinical Trials4
. Omeros Announces Successful Completion of PDE10 Phase 1 Multiple Ascending Dose Trial5
. Omeros Elucidates Mechanism of its PDE7 Inhibitors in Addiction6
. Omeros to Present at the Cowen and Company 33rd Annual Health Care Conference7
. Omeros Announces Toxicology Study Data from MASP-2 Inhibitor8
. Omeros Announces Positive OMS302 Safety Data in Phase 3 Clinical Trial9
. Omeros Announces Encouraging Data from Phase 1 Clinical Trial for PDE10 Program10
. Omeros to Present at the 24th Annual Piper Jaffray Health Care Conference11
. Omeros is Not Aware of Any Justification for Share Price Movement